产品
编 号：F493880
分子式：C186H275N51O59
分子量：4169.48
分子式：C186H275N51O59
分子量：4169.48
产品类型
规格
价格
是否有货
结构图
CAS No: 87805-34-3
产品详情
生物活性：
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.
体内研究：
GLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group.
体外研究：
Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells.
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.
体内研究：
GLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group.
体外研究：
Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备